Gen-Wealth Partners’s Iterum Therapeutics ITRM Stock Holding History

Gen-Wealth Partners’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-82,617	Closed	-$2.48K	–	735
2026 Q1	$2.48K	Sell	82,617 -2,013	-2%	-$505	﹤0.01%	634
2025 Q4	$28.4K	Buy	84,630 +2,583	+3%	+$1.39K	0.01%	442
2025 Q3	$55K	Buy	+82,047	New	+$64.3K	0.02%	381

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Gen-Wealth Partners's ITRM Position: Q2 2026 in Review

Gen-Wealth Partners sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 82,617 shares — an estimated $2.48K sold.

Gen-Wealth Partners first reported a position in ITRM in Q3 2025 and held it in 3 quarters. The position peaked at $55K in Q3 2025. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Gen-Wealth Partners reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Gen-Wealth Partners sold 82,617 Iterum Therapeutics shares in Q2 2026, an estimated $2.48K.
Gen-Wealth Partners first reported a position in Iterum Therapeutics in Q3 2025 and held it in 3 quarters.
Gen-Wealth Partners's Iterum Therapeutics position peaked at $55K in Q3 2025.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.